ACELYRIN (SLRN) announced that, in response to Tang Capital Partners’ continued rapid accumulation of 8.8% of ACELYRIN’S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan. The ACELYRIN Board and management team continue to engage with stockholders and are focused on maximizing stockholder value. Pursuant to the Rights Plan, the Company is issuing one right for each share of common stock as of the close of business on March 24, 2025. The rights will initially trade with ACELYRIN’s common stock and will become exercisable only if any person acquires 10% or more of the Company’s outstanding common stock
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLRN:
- Acelyrin says Concentra indication not expected to result in superior proposal
- Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger
- Biotech Alert: Searches spiking for these stocks today
- Acelyrin confirms unsolicited indication of interest from Concentra Biosciences
- Alumis price target lowered to $26 from $32 at Oppenheimer
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue